CooperBiomedical therapeutic div.
Exploring possibility of licensing to third parties the development, manufacture and sale of its therapeutic division's R&D projects and products as well as the sale of the therapeutic division's remaining operating units. Total fiscal 1984 R&D costs of $2.3 mil. were allocated to: alpha-1 antitrypsin, for the treatment of respiratory diseases; development of a liposome aerosol delivery system; refinement of human cell-produced viral inhibitors; and investigation of an immune system stimulator for use as an anticancer therapeutic.
You may also be interested in...
BVMed says the EU and the UK should set up a system of mutual recognition of medical device regulation to kick in when the UK’s EU exit transition period ends on 31 December.
HER3 may be a new target for anticancer antibody-drug conjugates; clinical investigators posted promising early stage clinical results with Daiichi Sankyo’s HER3 targeting antibody-drug conjugate, patritumab deruxtecan, at the recent ESMO virtual meeting.
After a slow start marked by product withdrawals and toxicity, recent deal-making activity has brought antibody-drug conjugates back from obscurity. But what has changed?